MW 254.24 Da, Purity >99%. Phytoestrogen, and soy isoflavone. Analog of genistein (ab120112). Various biological actions, including a weak estrogenic / antiestrogenic effect by binding to the nuclear estrogen receptor.
486-66-8
> 99%
Solid
254.24 Da
C15H10O4
5281708
Synthetic
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, ACLS, AHR_HUMAN, AIS, ANDR_HUMAN, AR, AR8, Ah receptor, Amine oxidase (flavin containing), Amine oxidase (flavin containing) A, Amine oxidase (flavin containing) B, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Aromatic hydrocarbon receptor, Aryl hydrocarbon receptor, Aryl hydrocarbon receptor precursor, Atherosclerosis, susceptibility to, included, BCC7, BCD541, BXR, CA 12, CA 7, CA IV, CA-VII, CA-XII, CA4, CAC1C_HUMAN, CACH 2, CACN 2, CACNL1A1, CAH12_HUMAN, CAH4_HUMAN, CAH7_HUMAN, CAR, CAR BETA, CARA, CCHL1A1, CP2C9_HUMAN, CPC12, CPC8, CPC9, CPCJ, CYP2C, CYP2C10, CYPIIC9, CaV1.2, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel voltage dependent L type alpha 1C subunit, Car 1, Car4, Carbonate dehydratase IV, Carbonate dehydratase VII, Carbonate dehydratase XII, Carbonic anhydrase 12, Carbonic anhydrase 4, Carbonic anhydrase 7, Carbonic anhydrase VII, Carbonic anhydrase XII, Carbonic dehydratase, Carbonic dehydratase IV, Carbonic dehydratase VII, Cellular tumor antigen p53, Class E basic helix-loop-helix protein 76, Component of gems 1, Constitutive activator of retinoid response, Constitutive active response, Constitutive androstane receptor, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, Cytochrome P450, family 2, subfamily C, polypeptide 9, DHPR alpha 1, DHPR alpha 1 subunit, DHTR, DKFZp686N23123, DNA binding protein, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), EC 4.2.1.1, EC=4.2.1.1, ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen-related receptor alpha, Estrra, FLJ20151, FLJ92943, GCCR, GCPS, GCRST, GCR_HUMAN, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, GR, Gemin-1, Glioma associated oncogene family zinc finger 3, Glucocorticoid receptor, Grl1, HD 7, HD 7B, HD 9, HDAC, HDAC 7B, HDAC 9B, HDAC 9FL, HDAC9_HUMAN, HDL cholesterol, augmented response of, to hormone replacement, included, HDRP, HGNC:348, HUMARA, HYSP1, Histone deacetylase 4/5 related protein, Histone deacetylase 7, Histone deacetylase 7B, Histone deacetylase 9, Histone deacetylase 9A, Histone deacetylase-related protein, HsT18816, KD, KIAA0744, Kennedy disease (KD), L type, LFS1, LQT8, MAO, MAO-A, MAO-B, MB67, MEF2 interacting transcription repressor protein, MEF2-interacting transcription repressor MITR, MGC149605, MGC88320, MGC97144, MITR, Microsomal monooxygenase, Monoamine oxidase, Monoamine oxidase A, Monoamine oxidase B, Monoamine oxidase type A, Monoamine oxidase type B, Mutant tumor protein 53, Myocardial infarction, susceptibility to, included, NR1B1, NR1I2_HUMAN, NR1I3_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, ONR 1, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000020135, OTTHUMP00000125198, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, OTTHUMP00000223567, OTTHUMP00000223568, OTTHUMP00000224066, OTTHUMP00000226924, Oncogene GLI3, Orphan nuclear receptor MB67, Orphan nuclear receptor NR1I3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P450 MP, P450 PB 1, P450C2C, P450IIC19, P450IIC9, P53_HUMAN, PAP A, PAPB, PAR, PAR q, PPD IV, PRR, Phosphoprotein p53, Pregnane X receptor, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, RNESTROR, RP17, Retinitis pigmentosa 17 (autosomal dominant), Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, S-mephenytoin 4-hydroxylase, SBMA, SMA, SMA 1, SMA 2, SMA 3, SMA 4, SMAX1, SMN1, SMN2, SMNT, SMN_HUMAN, SXR, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, Survival motor neuron protein, Survival of motor neuron 1, telomeric, T-BCD541, T18816, TFM, TRP53, TS, Testicular Feminization (TFM), Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Tumor antigen HOM-RCC-3.1.3, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Voltage dependent L type calcium channel alpha 1C subunit, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha subunit Cav1.2, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-gated calcium channel subunit alpha Cav1.2, Xenobiotic monooxygenase, Zinc finger protein GLI 3, alpha-1 polypeptide, androgen receptor splice variant 4b, bHLHe76, cardiac muscle, constitutive active receptor, constitutive androstane nuclear receptor variant 2, constitutive androstane nuclear receptor variant 3, constitutive androstane nuclear receptor variant 4, constitutive androstane nuclear receptor variant 5, cytochrome P-450 S-mephenytoin 4-hydroxylase, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, glucocorticoid nuclear receptor variant 1, hERR1, isoform 1, nr3c1, nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor), orphan nuclear hormone receptor, p53 tumor suppressor, pregnane X nuclear receptor variant 2, tumor antigen p55
MW 254.24 Da, Purity >99%. Phytoestrogen, and soy isoflavone. Analog of genistein (ab120112). Various biological actions, including a weak estrogenic / antiestrogenic effect by binding to the nuclear estrogen receptor.
486-66-8
> 99%
Solid
254.24 Da
C15H10O4
5281708
Synthetic
Soluble in DMSO to 100 mM.
Daidzein
Phytoestrogen, and soy isoflavone. Analog of genistein (ab120112). Various biological actions, including a weak estrogenic / antiestrogenic effect by binding to the nuclear estrogen receptor.
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O
InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H
ZQSIJRDFPHDXIC-UHFFFAOYSA-N
7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one
Ambient - Can Ship with Ice
-20°C
-20°C
Store under desiccating conditions, The product can be stored for up to 12 months
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120391, Daidzein, Phytoestrogen
ab47489 staining Bcl2 MCF7 cells treated with diadzein (ab120391), by ICC/IF. Decrease in Bcl2 expression correlates with increased concentration of diadzein, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab120391 (diadzein) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab47489 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com